Interim report January – September 2005

• Sales in the third quarter 2005 amounted to 126.6 MSEK (84.5) and sales in the period January – September 2005 to 292.0 MSEK (260.4). • The operating result for the third quarter amounted to –20.6 MSEK (-26.2) and the operating result for the nine month period to -58.3 MSEK (-62.3). Adjusted for non-recurring items the operating result for the third quarter amounted to -5.4 MSEK and the operating result for the period January – September to -43.1 MSEK. • The net result for the third quarter amounted to -27.6 MSEK (-31.4) and the net result for the first nine months amounted to -40.3 MSEK (-63.9). • Earnings per share for the third quarter amounted to -0.39 SEK (-0.54) and earnings per share for the period January - September to –0.61 SEK (-1.11). • In the third quarter there was a positive cash-flow from the current business to the amount of 2 MSEK. • An Extraordinary General Meeting in August decided to authorize the issue of new shares. • A directed share issue in September brought the company approx. net 94 MSEK. • In September it was decided to make a new share issue with preferential rights for the shareholders. The subscription period is in November. If the issue is fully subscribed, the company will gain approx. net 47 MSEK.

About Us

Biotage offers efficient separation technologies from analysis to industrial-scale and high-quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage’s products are used by public authorities, academic institutions, contract research and contract manufacturing organizations and in the pharmaceutical and food industries, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 390 employees and had sales of 748 MSEK in 2017. Biotage is listed on Nasdaq Stockholm. Website: www.biotage.com